Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal intermediate chain 3 (DNAI3) is a protein component of the axonemal dynein complex, which is essential for the structure and function of motile cilia and flagella[1][2][5]. It contains WD repeat motifs and enables Arp2/3 complex binding, negatively regulating actin nucleation as well as cell migration and invasion, primarily as part of cytoskeletal and ciliary functions[1][3][4][6][10]. DNAI3 has been associated with diseases involving ciliary dysfunction, most notably primary ciliary dyskinesia and certain developmental disorders such as occipital encephalocele[1]. Although it regulates important cell functions and has disease associations, it is not generally considered a direct therapeutic target such as a receptor, enzyme, or transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein axonemal intermediate chain 3 (DNAI3).